US EditionPublished • loading... • Updated
Blackstone, TPG plan to take Hologic private in a deal worth more than $13 billion
The $18.3 billion deal includes a 46% premium over pre-rumor stock prices and performance bonuses tied to breast health business revenue targets.
- Private equity firms Blackstone and TPG announced a take-private deal for Hologic, valuing the company at up to $18.3 billion, with a $79 per share offer including $76 cash plus up to $3 tied to revenue targets.
- About a 46% premium to May 23, 2025 prices underpins the deal terms, following a reported $16 billion offer that Hologic rejected before buyers increased their bid.
- The deal includes debt financing commitments from Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC, with equity from Blackstone and TPG funds, and minority investments from ADIA and GIC.
- Hologic shares rose nearly 4% to $74.62 Tuesday, the board unanimously approved the sale, but regulators and Hologic shareholders must still approve before a first half of next year close.
- Blackstone's move deepens its life-sciences focus and adds medical devices to its portfolio, as Hologic Inc., a 40-year-old diagnostics and women's health firm with about $4 billion in annual revenue and 7,000 employees, faces tariff-driven costs and slower revenue growth.
Insights by Ground AI
16 Articles
16 Articles
Blackstone and TPG Agree to $18 Billion Deal to Buy Hologic
Blackstone Inc. and TPG Inc. have agreed to acquire medical-device maker Hologic Inc. for as much as $18.3 billion, including debt, adding to the flurry of multibillion-dollar dealmaking by private equity firms in recent weeks.
·United States
Read Full Article
Coverage Details
Total News Sources16
Leaning Left4Leaning Right0Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 44%
C 56%
Factuality
To view factuality data please Upgrade to Premium
